Vice President-Global Project Leader
Meena Subramanyam, Ph.D., is an innovative scientific leader in the biopharmaceutical industry with extensive experience in drug development and translational sciences. She has contributed to the approval of eight first-in-class therapeutics and has published extensively in top-ranked peer-reviewed scientific journals on drug development, clinical biomarkers, pharmacokinetics/pharmacodynamics of therapeutics, bioanalytical methods, and clinical impact of immunogenicity. She has collaborated extensively with scientific thought leaders and has co-authored white papers with representatives from academia, industry, and U.S. and international regulatory agencies. She is a co-inventor of the Stratify JCV™ diagnostic test, the first U.S. Food and Drug Administration authorized blood test to measure JC virus antibodies, a risk stratification algorithm for progressive multifocal leukoencephalopathy based on JCV antibody level, and a diagnostic test to assess immunogenicity of TYSABRI (natalizumab), and has several patents pertaining to these innovations. Subramanyam is a recipient of the Healthcare Business Women Association’s Luminary Award in 2019. She has been a member of AAPS for over 15 years and served as conference chair of the 2017 AAPS National Biotechnology Meeting and chair of the Biotechnology section (2015-2016). She also served on the U.S. Pharmacopeia expert committee on antibody assays and the International Cytokines Standards Committee. She currently serves on the board of WEST, a Boston-based organization for the empowerment of women.
Tuesday, November 3, 2020
3:30 PM – 4:30 PM ET